PT Pharos and Albothyl Examination of Business Ethics in Indonesian Pharmaceutical Industry

Several institutions, including health authorities, began to investigate the effectiveness and safety of the product. Initial findings indicated that claims made by PT Pharos about Albothyl may not be supported by strong scientific evidence.

4. Public Reaction:

The case sparked outrage among consumers and attracted media attention. News of the complaints and investigations spread widely, raising controversy over marketing ethics and corporate responsibility.

In response, PT Pharos issued a statement to defend their claims and assert that Albothyl had gone through the testing process and obtained a distribution permit. However, criticism of the lack of transparency and strong scientific evidence continues.

Negative reactions from the public and media have led to a decline in trust in the Pharos brand. This has had an impact on product sales and the company's reputation in the pharmaceutical industry.

This case reflects the ethical challenges in the pharmaceutical industry, especially related to:
- Regulatory compliance, Ensuring that all product claims are supported by valid research.
- Transparency in marketing, Consumers have the right to clear and accurate information about the products they consume.
- Corporate social responsibility, Companies must consider the impact of their products on public health.

The cases of PT Pharos and Albothyl are a reminder of the importance of business ethics in the pharmaceutical industry. By prioritizing transparency, social responsibility, and regulatory compliance, companies can build trust with consumers and contribute to the development of a healthier industry. Collaborative efforts between companies, governments, and communities are essential to creating a more ethical and responsible environment in the marketing of health products.